Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
59
2023 to 2026
Breakthrough
15
Accelerated
17
Priority review
35
Orphan
33
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 8 | 2 |
| 2024 | 10 | 7 |
| 2025 | 14 | 5 |
| 2026 | 12 | 1 |
59 approvals
Newest first. Hover a badge for what it means.
- Pimjetmi (Pimicotinib) · Emd SeronoNov 10, 2026
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Etcamah (Camizestrant) · AstrazenecaSep 4, 2026
To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Jideytro (Zidesamtinib) · NuvalentJul 22, 2026
To treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer after receiving a ROS1 kinase inhibitor
- Revtorpyk (Gedatolisib) · CelcuityJul 14, 2026
In combination with fulvestran, to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting
- Cavhanza (Nilotinib) · CycleMay 29, 2026
- Decnupaz (Pivekimab Sunirine-Pvzy) · Abbvie INCMay 27, 2026
To treat adults with blastic plasmacytoid dendritic cell neoplasm
- Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor
- Jakafi Xr (Ruxolitinib Phosphate) · Incyte CorpMay 1, 2026
- Veppanu (Vepdegestrant) · Rigel PharmsMay 1, 2026
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Evdi (Trabectedin) · ApotexMay 1, 2026Original approval · NDA 220837Approval letter
- Hyrnuo (Sevabertinib) · Bayer HealthcareNov 19, 2025Original approval · NDA 219972NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat locally advanced or metastatic non-squamous non-small cell lung cancer with tumors that have activating HER2 tyrosine kinase domain activating mutations in patients who received a systemic therapy
- Inluriyo (Imlunestrant Tosylate) · Eli Lilly and COSep 25, 2025
To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab
- Keytruda Qlex (Pembrolizumab, Berahyaluronidase Alfa-Pmph) · Merck Sharp DohmeSep 19, 2025
To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab
- Koselugo (Selumetinib, Selumetinib Sulfate) · AstrazenecaSep 10, 2025
- Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids
- Hernexeos (Zongertinib) · Boehringer IngelheimAug 8, 2025Original approval · NDA 219042NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy
- Modeyso (Dordaviprone Hydrochloride) · ChimerixAug 6, 2025
To treat diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy
- Anzupgo (Delgocitinib) · Leo Pharma AsJul 23, 2025
To treat moderate-to-severe chronic hand eczema when topical corticosteroids are not advisable or produce an inadequate response
- Zegfrovy (Sunvozertinib) · DizalJul 2, 2025Original approval · NDA 219839NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations, as detected by an FDA-approved test, with disease progression on or after platinum-based chemotherapy
- Ibtrozi (Taletrectinib Adipate) · NuvationJun 11, 2025
To treat locally advanced or metastatic ROS1-positive non-small cell lung cancer
- Brukinsa (Zanubrutinib) · Beone Medicines USAJun 10, 2025
- Brukinsa (Zanubrutinib) · Beone Medicines USAJun 10, 2025
- Emrelis (Telisotuzumab Vedotin-Tllv) · Abbvie INCMay 14, 2025Original approval · BLA 761384NovelBreakthrough therapyAccelerated approvalPriority reviewApproval letter
To treat locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression after prior systemic therapy
- Avmapki Fakzynja CO-Pack (Copackaged) (Avutometinib Potassium, Defactinib Hydrochloride) · Verastem INCMay 8, 2025Original approval · NDA 219616NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy
- Penpulimab-Kcqx (Penpulimab-Kcqx) · Akeso BiopharmaApr 23, 2025
In combination with either cisplatin or carboplatin and gemcitabine, to treat adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC), or as a single agent while on or after platinum-based chemotherapy and at least one other prior line of therapy
- Nilotinib D-Tartrate (Nilotinib D-Tartrate) · CiplaFeb 19, 2025Original approval · NDA 218922Approval letter
- Romvimza (Vimseltinib) · Deciphera PharmsFeb 14, 2025
To treat symptomatic tenosynovial giant cell tumor for which surgical resection will potentially cause worsening functional limitation or severe morbidity
- Datroway (Datopotamab Deruxtecan-Dlnk) · Daiichi Sankyo INCJan 17, 2025
To treat unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease
- Ensacove (Ensartinib Hydrochloride) · XcoveryDec 18, 2024
To treat non-small cell lung cancer
- Unloxcyt (Cosibelimab-Ipdl) · Checkpoint Therapeutics INCDec 13, 2024
To treat cutaneous squamous cell carcinoma
- Bizengri (Zenocutuzumab-Zbco) · Merus N.V.Dec 4, 2024Original approval · BLA 761352NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat non-small cell lung cancer and pancreatic adenocarcinoma
- Ziihera (Zanidatamab-Hrii) · Jazz PharmsNov 20, 2024Original approval · BLA 761416NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer
- Danziten (Nilotinib Tartrate) · AzurityNov 7, 2024Original approval · NDA 219293Approval letter
- Vyloy (Zolbetuximab-Clzb) · AstellasOct 18, 2024
To treat gastric or gastroesophageal junction adenocarcinoma
- Itovebi (Inavolisib) · Genentech INCOct 10, 2024
To treat locally advanced or metastatic breast cancer
- Lazcluze (Lazertinib Mesylate) · Janssen BiotechAug 19, 2024
To treat non-small cell lung cancer
- Voranigo (Vorasidenib) · ServierAug 6, 2024
To treat Grade 2 astrocytoma or oligodendroglioma
- Imdelltra (Tarlatamab-Dlle) · Amgen INCMay 16, 2024Original approval · BLA 761344NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter
To treat extensive stage small cell lung cancer
- Rinvoq Lq (Upadacitinib) · AbbvieApr 26, 2024
- Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
- Ojemda (Tovorafenib) · Day One BiopharmsApr 23, 2024
To treat relapsed or refractory pediatric low-grade glioma
- Anktiva (Nogapendekin Alfa Inbakicept-Pmln) · Altor Bioscience, LLC, An Indirect Wholly-Owned SuApr 22, 2024
To treat bladder cancer
- Lumisight (Pegulicianine Acetate) · LumicellApr 17, 2024
To use as an optical imaging agent for the detection of cancerous tissue
- Retevmo (Selpercatinib) · Eli Lilly and COApr 10, 2024
- Tevimbra (Tislelizumab-Jsgr) · BeigeneMar 13, 2024
To treat unresectable or metastatic esophageal squamous cell carcinoma
- Ogsiveo (Nirogacestat Hydrobromide) · SpringworksNov 27, 2023
To treat adults with progressing desmoid tumors who require systemic treatment
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.